The global burden of advanced stage cervical cancer remains significant, particular in resource poor countries where effective screening programs are absent. Unfortunately, a proportion of patients will be diagnosed with advanced stage disease, and may suffer from persistent or recurrent disease despite treatment with combination chemotherapy and radiation. Patients with recurrent disease have a poor salvage rate, with an expected 5-year survival of less than 10%. Recently, significant gains have been made in the antiangiogenic arena; nonetheless the need to develop effective alternate targeted strategies is implicit. As such, a review of molecular targeted therapy in the treatment of this disease is warranted. In an era of biologics, combined therapy with cytotoxic drugs and molecular targeted agents, represents an exciting arena yet to be fully explored.
Angiogenesis Inhibitors/therapeutic use ; Antineoplastic Agents/*therapeutic use ; Female ; Histone Deacetylase Inhibitors/therapeutic use ; Humans ; Molecular Targeted Therapy/*methods ; Receptor, Epidermal Growth Factor/antagonists & inhibitors ; Salvage Therapy/methods ; Uterine Cervical Neoplasms/*drug therapy